Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation

Am J Obstet Gynecol. 2012 Nov;207(5):396.e1-8. doi: 10.1016/j.ajog.2012.08.001. Epub 2012 Aug 6.

Abstract

Objective: We sought to evaluate in women with twin gestation the relationship between 17-hydroxyprogesterone caproate (17-OHPC) concentration and gestational age at delivery and select biomarkers of potential pathways of drug action.

Study design: Blood was obtained between 24-28 weeks (epoch 1) and 32-35 weeks (epoch 2) in 217 women with twin gestation receiving 17-OHPC or placebo. Gestational age at delivery and concentrations of 17-OHPC, 17-hydroxyprogesterone, progesterone, C-reactive protein (CRP), and corticotrophin-releasing hormone were assessed.

Results: Women with higher concentrations of 17-OHPC delivered at earlier gestational ages than women with lower concentrations (P < .001). Women receiving 17-OHPC demonstrated significantly higher (P = .005) concentrations of CRP in epoch 1 than women receiving placebo but CRP values were similar in epoch 2 in both groups. A highly significant (P < .0001) positive relationship was observed between 17-OHPC concentration and progesterone and 17-hydroxyprogesterone concentrations at both epochs. Corticotropin-releasing hormone concentrations did not differ by treatment group.

Conclusion: 17-OHPC may adversely impact gestational age at delivery in women with twin gestation.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • 17 alpha-Hydroxyprogesterone Caproate
  • 17-alpha-Hydroxyprogesterone / blood
  • Adult
  • Biomarkers / blood
  • C-Reactive Protein / analysis
  • Corticotropin-Releasing Hormone / blood
  • Female
  • Gestational Age*
  • Humans
  • Hydroxyprogesterones / administration & dosage
  • Hydroxyprogesterones / adverse effects*
  • Hydroxyprogesterones / blood
  • Pregnancy
  • Pregnancy, Twin / drug effects*
  • Premature Birth / drug therapy*
  • Premature Birth / prevention & control
  • Progesterone / blood
  • Progestins / administration & dosage
  • Progestins / adverse effects*
  • Progestins / blood
  • Treatment Outcome

Substances

  • Biomarkers
  • Hydroxyprogesterones
  • Progestins
  • 17 alpha-Hydroxyprogesterone Caproate
  • Progesterone
  • 17-alpha-Hydroxyprogesterone
  • C-Reactive Protein
  • Corticotropin-Releasing Hormone

Grants and funding